Refractoriness in migraine treatment: What are we talking about?

Expert Review of Neurotherapeutics

Volumn 5, Issue 5, 2005, Pages 557-559

  Krymchantowski, Abouch Valenty ^a  

^a Headache Center of Rio   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; TRIPTAN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HEADACHE; HUMAN; MIGRAINE; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRESCRIPTION;

DISEASE MANAGEMENT; HUMANS; MIGRAINE DISORDERS;

EID: 26444514931     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.5.557     Document Type: Editorial

References (39)

1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 44(Suppl. 4), S24-S39 (1994).
2. Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45-68 (1995).
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1-160 (2004).
4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231-238 (1996).
5. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1-13 (1997).
6. Ferrari MD, Haan J. Drug treatment of migraine attacks. In: Headache. Blue Books of Practical Neurology. Goadsby P, Silberstein SD (Eds). Butterworth-Heinemann, MA, USA. 1997, 117-130 (1997).
7. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41, 638-645 (2001).
8. Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36-52 (2001).
9. Tfelt-Hansen P, Lipton RB. Prioritizing treatment. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Raven Press, NY, USA. 359-362 (1993).
10. 1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA. 411-438 (2000).
11. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3-9 (2002).
12. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18-22 (1998).
13. Visser WH, de Vriend RH, Jaspers MW, Ferrari MD. Sumatriptan- nonresponders: a survey in 366 migraine patients. Headache 36, 471-475 (1996).
14. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21-28 (1995).
15. Visser WH, de Vriend RH, Jaspers MW, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51 (1996).
16. Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA. 385-389 (2000).
17. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA. 121-246 (2001).
18. Yoon M-S, Savidou I, Diener H-C, Limmroth V. Evidence-based medicine in migraine prevention. Expert Rev. Neurotherapeutics 5(3), 333-341 (2005).
19. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23, 961-962 (2003).
20. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611-634 (2002).
21. Tfelt-Hansen P, Welch KMA. Prioritizing prophylactic treatment of migraine. In: The Headaches. 2nd Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA. 499-500 (2000).
22. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and racial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
23. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1-160 (2004).
24. The International Headache Society Clinical Trials Subcommittee. In: Guidelines for Controlled Trials of Drug in Migraine: Second Edition. International Headache Society Member's Handbook 2001/2002. Blackwell Science, Oxford, UK. 113-52 (2002).
25. Behin F, Behin B, Bigal ME, Lipton RB. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Headache 44, 487 (2004) (Abstract).
26. Robins L, Gokani T. Botulinum toxin type A for refractory chronic daily headache: long-term efficacy and tolerability. Headache 44, 487-488 (2004) (Abstract).
27. Krusz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21, 373 (2001) (Abstract).
28. Landy SH, McGinnis JE, McDonald SA. Clinical indicators of cutaneous allodynia in patients who treated early and late with 100 mg sumatriptan. Headache 44, 499 (2004) (Abstract).
29. Krymchantowski AV, Barbosa R, Moreira P, Adriano M. Adherence to treatment versus profile of previous health professional consultation in headache patients: a retrospective analysis. Headache 44, 511-512 (2004) (Abstract).
30. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2-3), 107-110 (2001).
31. Burstein R, Levy D, Collins B, Jakubowski M. Therapeutic approach to migraine with allodynia. Neurology 64(Suppl. 1), A151 (2005) (Abstract).
32. Rothrock JF, Parada V, Sims C, Key K, Walters N, Zweifler R. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache 45, 772-773 (2005) (Abstract).
33. Tietjen GE, Brandes JL, Digre KB et al. The interactive relationship of depression and somatic symptom severity to headache frequency and impact in women. Headache 45, 788-789 (2005) (Abstract).
34. Sternbach RA, Dalessio DJ, Kunzel M, Bowman GE. MMPI patterns in common headache disorders. Headache 19, 311-316 (1980).
35. Mongini F, Ibertis F, Ferla E. Personality characteristics before and after treatment of different head pain syndromes. Cephalalgia 14, 368-373 (1994).
36. Weeks RE, Baskin SM. Clinician attitudes and beliefs about headache diagnosis and treatment: educational factors that affect clinical practice. Headache 44, 510-511 (2004) (Abstract).
37. Eross EJ, Eross MD, Gladstone JP, David DW. Why migraine is misdiagnosed as sinus headache: the patient's perspective. Headache 44, 479 (2004).
38. Nicholson R, Olaughlin E, Gordon M. Headache care among different ethnicities: do disparities exist? Headache 45, 775 (2005) (Abstract).
39. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptans trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia 25, 124-131 (2005).